Latest News

• Presentation of XCELSIOR Observational Protocol for Real World Data Research        

   This is the future of medicine.  All patients should be followed as if they are in a clinical trial. This would allow researchers to figure out the best treatment options and find what works, and for whom. It would allow for the creation of synthetic control groups that are better than randomization for a trial, since ALL of the prognostic factors can be accounted for.   The free service will help practicing brain tumor doctors figure out which mutations are the most important and which drug combinations or clinical trials might be best for your patient.  

  
  
• 2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma        

   Very good results in a new Optune plus Pembrolizumab (Keytruda) trial for newly diagnosed glioblastoma.  They reported median progression free of 11.2 months compared to the original Optune trial without Pembrolizumab which had 6.7 months median progression free survival. The trial for Pembrolizumab alone for recurrent Glioblastoma only had a 2.8 month progression free survival.    This shows that Optune has an immunogenic effect, which the Pembrolizumab magnified.    Hopefully we will see an even better result when they start adding a vaccine to the mix!

  
  
• Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting        

   SNO is the big annual brain tumor meeting which is next week.   Novocure will have 32 presentations which is amazing. They are split between clinical and preclinical and we learn better how to use Optune with each presentation.  I will report after the conference on which have the biggest impact!